Alto Neuroscience (ANRO) Return on Capital Employed (2024 - 2026)
Alto Neuroscience (ANRO) posted Return on Capital Employed of 35.81% for Q1 2026, up 16.63% sequentially from 42.95% in Q4 2025, and up 593.0% YoY from 5.17% in Q1 2025.
Alto Neuroscience (ANRO) Return on Capital Employed (2024 - 2026) Analysis & Trends
Alto Neuroscience has reported Return on Capital Employed for 3 years, with the latest figure at 35.81% in Q1 2026.
- Quarterly Return on Capital Employed rose 593.0% year-over-year to 35.81% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.81% (up 593.0% YoY) and the FY2025 annual result came in at 39.09%, up 1712.0% from the prior year.
- Return on Capital Employed improved to 35.81% in Q1 2026 per ANRO's latest filing, from 42.95% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.97% in Q2 2024 and troughed at 46.24% in Q3 2025.
- A 3-year average of 38.45% and a median of 39.3% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 1683 bps in 2025, then surged 593 bps in 2026.
- Over 3 years, Return on Capital Employed stood at 39.3% in 2024, then slipped by 9 bps to 42.95% in 2025, then climbed by 17 bps to 35.81% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 35.81%, 42.95%, and 46.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -35.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.52% |
| Mar 31, 2026 | -35.81% |
| Dec 31, 2025 | -42.95% |
| Sep 30, 2025 | -46.24% |
| Jun 30, 2025 | -44.81% |
| Mar 31, 2025 | -41.74% |
| Dec 31, 2024 | -39.30% |
| Sep 30, 2024 | -35.12% |
| Jun 30, 2024 | -27.97% |
| Mar 31, 2024 | -32.08% |